Literature DB >> 23296342

Movement disorders in 2012: Advancing research towards novel therapeutic approaches.

Nikolaus R McFarland1, Michael S Okun.   

Abstract

Research in movement disorders in 2012 has improved our understanding of the pathogenic mechanisms of disease and led to development of potential novel therapeutic approaches. Key advances were linked to mechanisms underlying spread of neurodegenerative pathology, immunotherapy, stem cells, genetics and deep brain stimulation in parkinsonism and related disorders.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296342      PMCID： PMC3789847          DOI： 10.1038/nrneurol.2012.265

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

2.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

3.  A randomized trial of mesenchymal stem cells in multiple system atrophy.

Authors:  Phil Hyu Lee; Ji E Lee; Han-Soo Kim; Sook K Song; Hye Sun Lee; Hyo Suk Nam; June-Won Cheong; Yong Jeong; Hae-Jeong Park; Dong Joon Kim; Chung Mo Nam; Jong Doo Lee; Hyun Ok Kim; Young H Sohn
Journal:  Ann Neurol       Date:  2012-07       Impact factor: 10.422

4.  Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.

Authors:  Eun-Jin Bae; He-Jin Lee; Edward Rockenstein; Dong-Hwan Ho; Eun-Bi Park; Na-Young Yang; Paula Desplats; Eliezer Masliah; Seung-Jae Lee
Journal:  J Neurosci       Date:  2012-09-26       Impact factor: 6.167

5.  Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.

Authors:  Mahru C An; Ningzhe Zhang; Gary Scott; Daniel Montoro; Tobias Wittkop; Sean Mooney; Simon Melov; Lisa M Ellerby
Journal:  Cell Stem Cell       Date:  2012-06-28       Impact factor: 24.633

6.  A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms.

Authors:  Michael S Okun; Kelly D Foote; Samuel S Wu; Herbert E Ward; Dawn Bowers; Ramon L Rodriguez; Irene A Malaty; Wayne K Goodman; Donald M Gilbert; Harrison C Walker; Jonathan W Mink; Stacy Merritt; Takashi Morishita; Justin C Sanchez
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

7.  Increased thalamic gamma band activity correlates with symptom relief following deep brain stimulation in humans with Tourette's syndrome.

Authors:  Nicholas Maling; Rowshanak Hashemiyoon; Kelly D Foote; Michael S Okun; Justin C Sanchez
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

8.  Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Michael Mante; Leslie Crews; Brian Spencer; Anthony Adame; Christina Patrick; Margarita Trejo; Kiren Ubhi; Troy T Rohn; Sarah Mueller-Steiner; Peter Seubert; Robin Barbour; Lisa McConlogue; Manuel Buttini; Dora Games; Dale Schenk
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

9.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice.

Authors:  Kelvin C Luk; Victoria M Kehm; Bin Zhang; Patrick O'Brien; John Q Trojanowski; Virginia M Y Lee
Journal:  J Exp Med       Date:  2012-04-16       Impact factor: 14.307

10.  β band stability over time correlates with Parkinsonian rigidity and bradykinesia.

Authors:  S Little; A Pogosyan; A A Kuhn; P Brown
Journal:  Exp Neurol       Date:  2012-05-01       Impact factor: 5.330
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.